Protalix BioTherapeutics, Inc. (DE) (PLX) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the ProTalix Biotherapeutics Second Quarter 2025 Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I will now turn the conference over to our host, Mr. Mike Moyer with LifeSci Advisors. You may begin your conference. Thank you, Operator, and welcome to the ProTalix Biotherapeutics Second Quarter 2025 Financial Results and Business Update Conference Call. With me today are Dror Bashan, President and CEO of Portalix, I.L. Rubens, Senior Vice President and Chief Financial Officer. A press release announcing the financial results for the quarter in corporate updates was issued this morning and is now available on the Portalix website. Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings released in this teleconference include forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in the disclaimer and in Bratalex's filings with the U.S. Securities and Exchange Commission. I will now turn the call over to Mr. Bishan. Sure. Thank you, Mike, and thank you, everyone, for joining our second quarter of 2025 financial results and business update call. I will begin with... with reviewing our accomplishments over the quarter and recent weeks. Following my remarks, Eyal will provide a detailed review of our financial results. We will then open the line for questions, of course. In the first half of 2025, we experienced a 50% increase in revenues from selling goods compared to the same period last year. Revenue growth was driv...